Ask AI
ProCE Banner Activity

Data on HER2-Targeted Therapies in NSCLC, Practical Applications of HER2-Targeted Therapy, and Management of Treatment-Emergent Adverse Events

Slideset

Downloadable slides on the available data on HER2-targeted therapies in NSCLC, practical applications of HER2-targeted therapy, and management of treatment-emergent adverse events in NSCLC

Released: December 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity is designed to address the educational needs of oncologists, advanced practice providers, pharmacists, nurses, and other HCPs who care for patients with NSCLC. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply guideline-recommended testing and assessment for patients with NSCLC to identify patients with HER2 alterations who may benefit from HER2-directed ADC therapy

  • Integrate the latest clinical data and guidelines for treating HER2-mutant and overexpressing NSCLC, including emerging data for the use of HER2-directed ADCs in earlier lines of therapy

  • Implement personalized care plans for patients with NSCLC, including the use of reduced dosing regimens to mitigate and manage treatment-related adverse events in patients receiving HER2-directed ADC therapy